Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Astria Therapeutics (Nasdaq: ATXS), a biopharmaceutical company developing therapies for allergic and immunologic diseases, has granted stock options to three new employees under its 2022 Inducement Stock Incentive Plan. The grants, made on October 1, 2024, include options to purchase 52,000 shares of Astria's common stock at an exercise price of $11.43 per share, equal to the closing price on the grant date.
These options will vest over four years, with 25% vesting on the first anniversary of the employee's start date and the remaining shares vesting monthly over the following 36 months. The grants comply with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms of the 2022 Inducement Stock Incentive Plan and individual award agreements.
Astria Therapeutics (Nasdaq: ATXS), un'azienda biofarmaceutica che sviluppa terapie per malattie allergiche e immunologiche, ha concesso opzioni su azioni a tre nuovi dipendenti secondo il suo Piano di Incentivazione per l'Induzione 2022. Le concessioni, effettuate il 1 ottobre 2024, includono opzioni per acquistare 52.000 azioni delle azioni ordinarie di Astria a un prezzo di esercizio di 11,43 dollari per azione, pari al prezzo di chiusura nel giorno della concessione.
Queste opzioni matureranno in quattro anni, con il 25% che matura nel primo anniversario della data di assunzione del dipendente e le azioni rimanenti che matureranno mensilmente nei successivi 36 mesi. Le concessioni sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4) e sono soggette ai termini del Piano di Incentivazione per l'Induzione 2022 e agli accordi di assegnazione individuale.
Astria Therapeutics (Nasdaq: ATXS), una compañía biofarmacéutica que desarrolla terapias para enfermedades alérgicas e inmunológicas, ha otorgado opciones sobre acciones a tres nuevos empleados bajo su Plan de Incentivos para la Inducción 2022. Las concesiones, realizadas el 1 de octubre de 2024, incluyen opciones para comprar 52,000 acciones de acciones ordinarias de Astria a un precio de ejercicio de 11.43 dólares por acción, igual al precio de cierre en la fecha de concesión.
Estas opciones se adquirirán en un período de cuatro años, con el 25% adquiriéndose en el primer aniversario de la fecha de inicio del empleado y las acciones restantes adquiriéndose mensualmente durante los siguientes 36 meses. Las concesiones cumplen con la Regla de Cotización Nasdaq 5635(c)(4) y están sujetas a los términos del Plan de Incentivos para la Inducción 2022 y a los acuerdos de adjudicación individuales.
Astria Therapeutics (Nasdaq: ATXS)는 알레르기 및 면역 질환을 위한 치료제를 개발하는 생명공학 회사로, 2022 유도 주식 인센티브 플랜에 따라 세 명의 신입 직원에게 주식 옵션을 부여했습니다. 이 부여는 2024년 10월 1일에 이루어졌으며, Astria의 보통주 52,000주를 주당 11.43달러의 행사 가격으로 구매할 수 있는 옵션을 포함합니다. 이 가격은 부여일의 종가와 같습니다.
이 옵션은 4년 동안 분할되어 만료됩니다, 직원의 시작일 1주년에는 25%가 만료되고, 나머지 주식은 다음 36개월 동안 매달 만료됩니다. 이 부여는 나스닥 상장 규칙 5635(c)(4)에 부합하며, 2022 유도 주식 인센티브 플랜 및 개별 보상 계약의 조건에 따라 다릅니다.
Astria Therapeutics (Nasdaq: ATXS), une entreprise biopharmaceutique développant des thérapies pour les maladies allergiques et immunologiques, a accordé des options d'achat d'actions à trois nouveaux employés dans le cadre de son Plan d'incitation à l'induction 2022. Les attributions, effectuées le 1er octobre 2024, comprennent des options pour acheter 52 000 actions des actions ordinaires d'Astria à un prix d'exercice de 11,43 dollars par action, ce qui correspond au prix de clôture à la date d'attribution.
Ces options s'acquitteront sur quatre ans, avec 25 % s'acquittant à l'anniversaire du début de l'employé et les actions restantes s'acquittant mensuellement au cours des 36 mois suivants. Les attributions sont conformes à la Règle de cotation Nasdaq 5635(c)(4) et sont soumises aux conditions du Plan d'incitation à l'induction 2022 ainsi qu'aux accords d'attribution individuels.
Astria Therapeutics (Nasdaq: ATXS), ein biopharmazeutisches Unternehmen, das Therapien für allergische und immunologische Erkrankungen entwickelt, hat Aktiensoptionen an drei neue Mitarbeiter im Rahmen seines Anreizplans von 2022 gewährt. Die Vergaben, die am 1. Oktober 2024 erfolgt sind, beinhalten die Option, 52.000 Aktien der Stammaktien von Astria zu einem Ausübungspreis von 11,43 US-Dollar pro Aktie zu kaufen, was dem Schlusskurs am Vergabedatum entspricht.
Diese Optionen verfallen über einen Zeitraum von vier Jahren, wobei 25 % am ersten Jahrestag des Beginns des Mitarbeiters verfallen und die verbleibenden Aktien monatlich über die folgenden 36 Monate verfallen. Die Vergaben entsprechen der Nasdaq-Listing-Regel 5635(c)(4) und unterliegen den Bedingungen des Anreizplans von 2022 sowie den individuellen Vergabevereinbarungen.
- Astria Therapeutics is attracting new talent with stock option incentives
- The company is expanding its workforce, potentially indicating growth
- None.
The options were granted as an inducement material to three employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241002054518/en/
Astria:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics, Inc.
FAQ
How many stock options did Astria Therapeutics (ATXS) grant on October 1, 2024?
What is the exercise price of the stock options granted by Astria Therapeutics (ATXS)?
How do the stock options granted by Astria Therapeutics (ATXS) vest?
Under which plan did Astria Therapeutics (ATXS) grant these stock options?
